Spero Therapeutics (SPRO) Operating Leases (2019 - 2026)

Spero Therapeutics (SPRO) has reported Operating Leases for 8 consecutive years, with $43000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 97.57% year-over-year to $43000.0; the trailing twelve-month figure through Jun 2026 stood at $43000.0 (down 97.57% YoY), and the FY2025 full-year result was $939000.0, down 63.19% from the prior year.
• Operating Leases eased to $43000.0 in Q2 2026 per SPRO's latest filing, from $507000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $5.7 million in Q1 2022 and bottomed at $43000.0 in Q2 2026.
• Historically, Operating Leases has averaged $3.2 million across 5 years, with a median of $3.4 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Operating Leases retreated 14.06% in 2022, then plunged 97.57% in 2026.
• Over 5 years, Operating Leases stood at $5.0 million in 2022, then retreated by 22.84% to $3.8 million in 2023, then slumped by 33.31% to $2.6 million in 2024, then slumped by 63.19% to $939000.0 in 2025, then sank by 95.42% to $43000.0 in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $43000.0, $507000.0, and $939000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.